AGN.AU Argenica Therapeutics Ltd

Healthcare Biotechnology Australian Securities Exchange
0.1150 AUD
Close of Oct 30, 2026
0.0870 0.3450
Market cap
AUD 14.8M
P/E
-
P/B
2.50x
ROE
166.1%
Dividend yield
-
Fundamental score
1.4/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is AGN.AU undervalued?

Graham number

The Graham number of Argenica Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Argenica Therapeutics Ltd fundamental analysis

7 of 22 checks passed

ROE 2/2

High return on equity (166.1%), above 20%.

ROA 1/1

Return on assets (150.5%) is above the industry median (-51.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (81.1%) is above the industry median (-5.3%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 0/1

No interest expense reported.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (2.5x) is below the industry median (4.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Argenica Therapeutics Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Argenica Therapeutics Ltd

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.

Full company profile